Oscar Health, Inc.
30.99USD
-2.3300 (-6.99%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on OSCR.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 64.9M | 21.4M | 20.6M | 28.6M | 18.7B | 20.8B |
| Q1 | 18.5M | 5.0M | 5.6M | 4.3M | 5.7M | — |
| Q2 | 20.5M | 5.1M | 5.2M | 6.5M | 6.1M | — |
| Q3 | 19.4M | 5.5M | 4.9M | 8.8M | 4.7B | — |
| Q4 | 6.6M* | 5.7M* | 4.8M* | 9.0M* | 4.5B | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -2.85 | -1.22 | .100 | -1.69 | 1.94 | 2.22 |
| Q1 | -.360 | -.180 | .620 | .920 | 2.07 | — |
| Q2 | -.530 | -.070 | .200 | -.890 | 1.10 | — |
| Q3 | -.910 | -.290 | -.220 | -.530 | -.173 | — |
| Q4 | -1.06* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| -.677* |
| -.578* |
| -1.34* |
| -1.08 |
| — |
Debt level and coverage